Exergame and Robotic Therapy Impact on Tenascin-C and Functional Outcome on Stroke Patients
Launched by HASANUDDIN UNIVERSITY · Aug 17, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different types of therapy can help improve hand function in patients who have had a stroke. Specifically, it will compare three approaches: robotic therapy, exergame therapy (which uses video games to encourage movement), and standard rehabilitation therapy. The goal is to see which method is most effective in helping patients recover their abilities over time and to understand how these therapies might affect a specific protein in the body called Tenascin-C, which is linked to healing.
To be eligible for this trial, participants need to have experienced a stroke and be in stable health, meaning their vital signs and neurological condition are steady. They must also be able to understand the consent process and watch television from about one meter away. However, those with certain conditions, like severe cognitive disorders or uncontrolled medical issues, may not qualify. If chosen to participate, individuals will engage in therapy sessions and be monitored regularly to evaluate their progress. This study is currently looking for participants of all ages and genders who meet the criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients after ischemic or hemorrhagic stroke
- • stable hemodynamics and neurologic state.
- • Patients have never undergone treatment with any intervention
- • Able to watch television with or without glasses from a distance of 1 meter.
- • Patients can understand informed consent to participate in research
- Exclusion Criteria:
- • Patients with a history of seizures or epilepsy.
- • Patients with severe cognitive disorders that can interfere with research objectives (MMSE score \<24).
- • Patients with field deficits or severe vision disorders.
- • The patient is unable to sit upright without help.
- • Patients with significant pain in the affected upper limb.
- • Patients with significant sensory decreases in the upper limb that are affected
- • Patients with other medical conditions (musculoskeletal, neuromuscular, cardio respiration) are uncontrolled and are at risk of disrupting the ability to exercise.
- • Dropout Criteria
- • Patients who were declared dead
- • Refusing to continue the training session or less \< 50% of all sessions.
- • Experiencing hemodynamic and neurological disorders during the training program process.
- • Experiencing cybersickness twice in successive training sessions
About Hasanuddin University
Hasanuddin University is a prestigious academic institution based in Indonesia, dedicated to advancing healthcare research and education. As a clinical trial sponsor, the university leverages its extensive expertise in medical and health sciences to conduct innovative research aimed at improving patient outcomes and addressing public health challenges. With a commitment to ethical research practices and collaboration with local and international partners, Hasanuddin University plays a vital role in contributing to the body of knowledge in clinical sciences, fostering advancements in treatment methodologies, and enhancing healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Makassar, South Sulawesi, Indonesia
Makassar, South Sulawesi, Indonesia
Patients applied
Trial Officials
Rumaisah Hasan, MD
Principal Investigator
Hasanuddin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported